Læknablaðið - 15.12.1999, Blaðsíða 40

974
LÆKNABLAÐIÐ 1999; 85
HEIMIDLIR
1. Guðmundsson JA. Breytingaskeið og hormónameðferð.
Fyrri grein. Læknaneminn 1995; 1: 22-7.
2. Champe PC, Harvey RA. Biochemistry. 2nd ed. Philadel-
phia: J.B. Lippincott Company; 1994: 213-22.
3. Belchetz P. Endocrinology of the menopause. Practitioner
1990;234:491-3.
4. Speroff L, Glass RH, Kase NG. Clinical Gynecologic
Endocrinology and Infertility. 5th ed. Baltimore: Williams
& Wilkins; 1994: 583-649.
5. Campagnoli C, Lesca L, Cantamessa C, Peris C. Long-term
hormone replacement treatment in menopause: new choices,
old apprehensions, recent fmdings. Maturitas 1993; 18:21-46.
6. Jóhannesson A. Beinþynning. Læknablaðið 1988; 74:77-80.
7. Myers LS, Dixen J, Morrissette D, Carmichael M, David-
son JM. Effects of estrogen, androgen, and progestin on
sexual psychophysiology and behavior in postmenopausal
women. J Clin Endocrinol Metabol 1990; 70: 1124-31.
8. Fignon A, Marret H, Lansac J. Bilateral ovarian removal
during hysterectomy: what is done and what should be
done. Eur J Obstet Gynecol Reprod Biol 1998; 76: 201-5.
9. Matthews KA, Meilahn E, Kuller LH, Kelsey SF, Caggiula
AW, Wing RR. Menopause and risk factors for coronary
heart disease. N Eng J Med 1989; 321: 641-6.
10. Sherwin BB, Gelfand MM. Sex steroids and affect in the
surgical menopause: a double-blind, cross-over study.
Psychoneuroendocrinology 1985; 10: 325-35.
11. Wiklund I, Karlberg J, Lindgren R, Sandin K, Mattson LA.
A Swedish version of the women's health questionnaire. A
measurement of postmenopausal complaints. Acta Obst
Gynecol Scand 1993; 72: 648-55.
12. Corson SL. A decade of experience with transdermal estro-
gen replacement therapy: overview of key pharmacologic
and clinical fmdings. Int J Fertil 1993; 38: 79-91.
13. Jensen J, Christiansen C, R0dbro P. Cigarette smoking,
serum estrogens, and bone loss during hormone-replace-
ment therapy early after menopause. N Eng J Med 1985;
313:973-5.
14. Rees MCP. The need to improve compliance to HRT. Br J
Obstet Gynaecol 1997; 104/Suppl. 16: 1-3.
15. Elíasson JH, Tryggvadóttir L, Tulinius H, Guðmundsson
JA. Hormónameðferð kvenna á íslandi. Læknablaðið 1998;
84: 25-31.
16. Gambacciani M, Spinetti A, Taponeco F, Ciaponi M, Cima
GP, Teti GC, et al. Prospective evaluation of calcium and
estrogen administration on bone mass and metabolism after
ovariectomy. Gynecol Endocrinol 1995; 9: 131-5.
17. Witteman JCM, Grobbee DE, Kok FJ, Hofman A, Valken-
burg HA. Increased risk of atherosclerosis in women after
the menopause. Br Med J 1989; 298: 642-4.
18. Lip GY, Blann AD, Jones AF, Beevers DG. Eífects of hor-
mone-replacement therapy on hemostatic factors, lipid fac-
tors, and endothelial function in women undergoing surgi-
cal menopause: implications for prevention of athero-
sclerosis. Am Heart J 1997; 134: 764-71.
19. Reeve J. Bone tumover and trabecular plate survival after
artificial menopause. Br Med J Clin Res Ed 1987; 295
(6601): 757-60.
20. Mott S. Bone mass measurements: reasons to be cautious.
BrMedJ 1994; 308: 931-2.
21. Piver MS, Rosen B. The role ofprophylactic oophorectomy.
In: Gershenson DM, Macguire WT, eds. Ovarian cancer:
controversies in management. London: Churchill Living-
stone; 1998: 17-40.
22. Hunter M, Battersby R, Whitehead M. Relationships bet-
ween psychological symptoms, somatic complaints and
menopausal status. Maturitas 1986; 8: 217-28.